Key result
A weighted 13-SNP genetic risk score was significantly associated with prior cardiovascular disease (OR 1.51; 95% CI 1.22-1.86; P=0.0002) and CVD mortality (HR 1.35; 95% CI 1.10-1.81; P=0.04).
Why the study?
Do genetic risk scores predict cardiovascular disease, coronary calcification, and mortality in European Americans with type 2 diabetes?
Cohort (n=1,175)
Do genetic risk scores predict cardiovascular disease, coronary calcification, and mortality in European Americans with type 2 diabetes?
Genetic risk scores based on 13 or 30 SNPs are significantly associated with cardiovascular disease, coronary calcification, and mortality in European Americans with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports GRS for CVD risk stratification in type 2 diabetes; leaves open prospective validation against clinical scores.
OBJECTIVE Given the high rates of cardiovascular disease (CVD) and associated mortality in individuals with type 2 diabetes, identifying and understanding predictors of CVD events and mortality could help inform clinical management in this high-risk group. Recent large-scale genetic studies may provide additional tools in this regard. RESEARCH DESIGN AND METHODS Genetic risk scores (GRSs) were constructed in 1,175 self-identified European American (EA) individuals comprising the family-based Diabetes Heart Study based on 1) 13 single nucleotide polymorphisms (SNPs) and 2) 30 SNPs with previously documented associations with CVD in genome-wide association studies. Associations between each GRS and a self-reported history of CVD, coronary artery calcified plaque (CAC) determined by noncontrast computed tomography scan, all-cause mortality, and CVD mortality were examined using marginal models with generalized estimating equations and Cox proportional hazards models. RESULTS The weighted 13-SNP GRS was associated with prior CVD (odds ratio [OR] 1.51 [95% CI 1.22-1.86]; P = 0.0002), CAC (β-coefficient [β] 0.22 [0.02-0.43]; P = 0.04) and CVD mortality (hazard ratio [HR] 1.35 [1.10-1.81]; P = 0.04) when adjusting for the other known CVD risk factors: age, sex, type 2 diabetes affection status, BMI, current smoking status, hypertension, and dyslipidemia. The weighted 30-SNP GRS was also associated with prior CVD (OR 1.33 [1.08-1.65]; P = 0.008), CAC (β 0.29 [0.08-0.50]; P = 0.006), all-cause mortality (HR 1.28 [1.05-1.56]; P = 0.01), and CVD mortality (HR 1.46 [1.08-1.96]; P = 0.01). CONCLUSIONS These findings support the utility of two simple GRSs in examining genetic associations for adverse outcomes in EAs with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Cox et al. (2014) conducted a cohort in Type 2 diabetes (n=1,175). Genetic risk scores (13-SNP and 30-SNP) was evaluated on Prior cardiovascular disease (OR 1.51, 95% CI 1.22-1.86, p=0.0002). A weighted 13-SNP genetic risk score was significantly associated with prior cardiovascular disease (OR 1.51; 95% CI 1.22-1.86; P=0.0002) and CVD mortality (HR 1.35; 95% CI 1.10-1.81; P=0.04).
Synapse has enriched 10 related papers. Consider them for comparative context: